170 related articles for article (PubMed ID: 33082357)
1. Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer.
Tsai LH; Hsu KW; Chiang CM; Yang HJ; Liu YH; Yang SF; Peng PH; Cheng WC; Wu HH
Sci Rep; 2020 Oct; 10(1):17817. PubMed ID: 33082357
[TBL] [Abstract][Full Text] [Related]
2. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
3. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
4. Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines.
Wu HH; Hwang-Verslues WW; Lee WH; Huang CK; Wei PC; Chen CL; Shew JY; Lee EY; Jeng YM; Tien YW; Ma C; Lee WH
J Exp Med; 2015 Mar; 212(3):333-49. PubMed ID: 25732306
[TBL] [Abstract][Full Text] [Related]
5. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
Mimeault M; Johansson SL; Senapati S; Momi N; Chakraborty S; Batra SK
Cancer Lett; 2010 Sep; 295(1):69-84. PubMed ID: 20303649
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Matsuzawa F; Kamachi H; Mizukami T; Einama T; Kawamata F; Fujii Y; Fukai M; Kobayashi N; Hatanaka Y; Taketomi A
BMC Cancer; 2021 Feb; 21(1):200. PubMed ID: 33637083
[TBL] [Abstract][Full Text] [Related]
7. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.
Zhang Z; Han H; Rong Y; Zhu K; Zhu Z; Tang Z; Xiong C; Tao J
J Exp Clin Cancer Res; 2018 Nov; 37(1):291. PubMed ID: 30486896
[TBL] [Abstract][Full Text] [Related]
9. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
10. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of the human tumor antigen mucin by gemcitabine on the pancreatic cancer cell line capan-2.
Dorn DC; Harnack U; Pecher G
Anticancer Res; 2004; 24(2B):821-5. PubMed ID: 15161033
[TBL] [Abstract][Full Text] [Related]
13. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.
Urey C; Andersson B; Ansari D; Sasor A; Said-Hilmersson K; Nilsson J; Andersson R
Scand J Gastroenterol; 2017 May; 52(5):595-600. PubMed ID: 28270046
[TBL] [Abstract][Full Text] [Related]
14. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
Kim R; Yamauchi T; Husain K; Sebti S; Malafa M
Anticancer Res; 2015 Sep; 35(9):4599-604. PubMed ID: 26254348
[TBL] [Abstract][Full Text] [Related]
15. Natural Anti-Cancer Agents: Implications in Gemcitabine-Resistant Pancreatic Cancer Treatment.
Marasini B; Sahu RP
Mini Rev Med Chem; 2017; 17(11):920-927. PubMed ID: 28302042
[TBL] [Abstract][Full Text] [Related]
16. Development and
Urey C; Hilmersson KS; Andersson B; Ansari D; Andersson R
Anticancer Res; 2017 Nov; 37(11):6031-6039. PubMed ID: 29061782
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.
Bafna S; Kaur S; Momi N; Batra SK
Br J Cancer; 2009 Oct; 101(7):1155-61. PubMed ID: 19738614
[TBL] [Abstract][Full Text] [Related]
18. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Iwanski GB; Lee DH; En-Gal S; Doan NB; Castor B; Vogt M; Toh M; Bokemeyer C; Said JW; Thoennissen NH; Koeffler HP
Br J Pharmacol; 2010 Jun; 160(4):998-1007. PubMed ID: 20590594
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Zhang Z; Duan Q; Zhao H; Liu T; Wu H; Shen Q; Wang C; Yin T
Cancer Lett; 2016 Nov; 382(1):53-63. PubMed ID: 27576197
[TBL] [Abstract][Full Text] [Related]
20. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
